BioCentury
ARTICLE | Clinical News

1 regulatory update

November 24, 2003 8:00 AM UTC

The FDA granted Fast Track designation to Biosyn's C31G vaginal gel to reduce HIV transmission. C31G is entering Phase III trials. ...